UPADACITINIB

Brand name:

• Rinvoq®

Pharmaceutical company:

Abbvie Pty Ltd

Condition/indication:
(therapeutic use)

• Severe active rheumatoid arthritis

PBAC Submission type:

Change to listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – December 2023

Related medicines:

• ADALIMUMAB UPADACITINIB

Submission received for:

December 2023 PBAC meeting

Opportunity for consumer comment:

Open 27/07/2022 and close 21/09/2022 (see PBS Website)

PBAC meeting:

Held on 06/12/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

05/01/2024

Lodgement of required documentation:

12/01/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 01/02/2024

Status:

Finalised

Government processes:

Commenced on 01/02/2024

Medicine listed on the PBS:

01/05/2024 (see PBS schedule)

---